企业所得税检查工作管理办法(试行)
国家税务总局
企业所得税检查工作管理办法(试行)
第一章 总则
第一条 为加强企业所得税检查工作,促进企业所得税管理规范化,保证企业所得税法规、规章的正确贯彻执行,根据《中华人民共和国税收征收管理法》和《中华人民共和国企业所得税暂行条例》的有关规定,制定本办法。
第二条 本办法适用于税务机关对企业所得税纳税人(以下简称纳税人)实施的企业所得税检查工作,包括企业所得税日常检查和企业所得税专项检查。
第三条 企业所得税检查是指税务机关依照有关的税收法律、法规和规章,对纳税人特定时期(通常指一个或几个纳税年度)申报缴纳企业所得税情况进行的检查和处理工作,目的是防范和查处纳税人偷逃企业所得税的行为或避税行为。
第四条 企业所得税日常检查是指税务机关根据年度检查工作计划,对纳税人以前年度申报缴纳企业所得税情况进行的全面例行检查。企业所得税专项检查是指税务机关根据上级税务机关指定的对象、范围或企业所得税纳税事项,对有关纳税人一定期间申报缴纳企业所得税情况进行的有针对性的检查。
第五条 企业所得税检查是企业所得税管理工作的重要组成部分。根据企业所得税规范化管理的要求,抓好企业所得税检查工作是各级税务机关的重要职责。企业所得税检查工作可分为确定检查对象的规划选案、检查工作的组织实施和检查工作的审理终结等环节。
第六条 企业所得税检查原则上应该在纳税人年度企业所得税申报结束之后进行。
第七条 企业所得税检查的选案、实施和审理终结职能应当适当分离。
第八条 国家税务局和地方税务局应按企业所得税征收管理职责范围划分检查权限。企业所得税检查原则上由企业经营管理所在地主管税务机关组织实施;企业所得税检查权发生争议的,由有关税务机关本着有利检查的原则协商确定;协商未能取得一致意见的,报上级税务机关裁定。
第二章 规划选案
第九条 税务机关应制定企业所得税检查计划。企业所得税日常检查计划由主管税务机关制定,专项检查计划由上级税务机关制定。
第十条 企业所得税日常检查是企业所得税检查工作的重点,企业所得税日常检查对象的确定,要逐步实现以规定指标和项目由计算机处理分析选案为主,以随机抽样为辅。为提高企业所得税日常检查工作质量,各地应逐步建立企业所得税申报的计算机处理分析系统,采用科学的综合性指标进行选案。税务机关应根据计算机储存的数据信息,计算出企业所得税申报纳税的有关逻辑性、趋势性和合理性指标,以相关指标的重要性为权数,建立企业所得税日常检查选案的计分系统。有关分值标准要逐步建立完善,实现专业化管理,不断研究、修正,对分值标准要建立保密制度,要实行档案化管理。
第十一条 对暂不具备计算机处理分析选案条件的地区,可继续采用人工归集分析方法确定企业所得税日常检查的对象。采用人工归集分析方法选案,负责选案的人员应具备一定的企业所得税征收管理工作经验。
第十二条 企业所得税专项检查是企业所得税日常检查的必要补充。企业所得税专项检查应根据以前年度企业所得税汇算清缴和日常检查中反映的问题,根据企业所得税政策法规变化的情况,通过有针对性的调查研究,确定专项检查的范围、对象和内容。
第十三条 税务机关在确定年度企业所得税检查工作计划时,要根据检查人员配备情况,综合考虑企业所得税日常检查和专项检查,企业所得税检查和其他税种的检查的工作量。对纳税人同一纳税年度的企业所得税检查,原则上不得重复进行;对重点税源大户和上市股份公司可每个纳税年度检查一次;对其他纳税人每三个纳税年度至少检查一次。
第三章 组织实施
第十四条 主管税务机关要统一调配力量组织实施企业所得税检查,将参加检查的人员划分为若干检查小组,把检查任务具体落实到检查小组,每个检查小组至少由2个以上检查人员组成。
第十五条 检查小组在实施检查前要详细了解被检查纳税人的基本情况,包括生产经营情况、财务管理情况、同业经营情况、企业所得税纳税情况、以前年度的企业所得税和其他税种检查发现的问题,确定企业所得税检查的范围、重点、策略、时间、进度、人员分工等。
第十六条 企业所得税检查应区别纳税人的情况,分别实施案头审核、调账检查和实地检查。
第十七条 企业所得税的案头审核是对纳税人填报的企业所得税申报表及附表资料的审查核对和税额评定。企业所得税的案头审核以数据验算和指标分析复核为主。对企业所得税申报表的有关收入、扣除项目或政策运用有疑问的,主管税务机关可向纳税人发出问询函,实施函查,要求纳税人作出说明或补充资料。
第十八条 企业所得税的调账检查是将纳税人的账簿、凭证和有关资料,调到税务机关进行检查。对内部管理制度健全、财务管理规范、账证完整的纳税人,应尽可能实行调账检查。
第十九条 企业所得税的实地检查是税务检查人员深入纳税人的经营管理现场进行检查。对内部管理制度不健全的纳税人,或内部管理制度健全,但因种种原因不能调账检查的纳税人,可进行实地检查。
第二十条 实施企业所得税检查要详细查阅纳税人的账簿、凭证;查阅与生产经营有关的重要文件,如供销合同、董事会或企业经理会议记录;与有关人员进行座谈;如有必要,可对相关实物资产进行盘点、核对。
第二十一条 企业所得税检查必须保留完整的检查工作底稿。企业所得税检查工作底稿是企业所得税检查人员在实施检查过程中形成的全部工作记录和取得的证据、资料。包括具体检查计划、检查过程记录、检查发现问题和证据、初步处理意见和政策依据。
第二十二条 企业所得税检查主要是对纳税人应纳税收入总额、准予扣除项目、适用税率及优惠政策的合理性、合法性和真实性进行的审核和检查。根据纳税人的具体情况可以实施全面检查,也可以抽查。
第二十三条 收入总额的检查范围包括纳税人取得的一切收入。收入总额检查的目标是,确定应税收入的完整性,检查纳税人是否有隐瞒未申报的应纳税收入;确定应税收入的确认的合法性,检查纳税人应税收入的确认是否符合企业所得税法规和规章规定的实现原则和方法,有否推迟或提前确认收入的情况;确定应税收入与非应税收入划分的准确性,检查纳税人有否将应税收入作为非应税收入申报的情况。
第二十四条 准予扣除项目的检查范围包括对纳税人申报的与应纳税收入有关的全部扣除项目。扣除项目检查的目标是,确定申报的扣除项目的真实性,检查纳税人有否虚报扣除;确定申报的扣除项目与应纳税收入的配比性,检查纳税人有否将非应税收入的费用申报为与应税收入有关的扣除,有否将资本性支出作为期间费用扣除等;确定申报的扣除项目的必要性、合理性,检查纳税人申报的扣除项目是否是为取得应纳税收入的正常支出,是否符合会计惯例和经营常规,是否符合企业所得税法规、规章规定的标准。
第二十五条 企业所得税税率和优惠政策的检查范围包括纳税人适用的税率和优惠政策。检查目标是,确定纳税人申报的适用税率和优惠政策的合法性,检查纳税人有否错用税率和优惠政策的情况;确定纳税人适用的优惠政策是否符合规定的批准程序等。
第四章 审理终结
第二十六条 企业所得税检查实施完成后,对未发现纳税人有违反企业所得税法规和规章的行为或偷逃税等问题的,检查小组应及时填写检查终结结论,经业务管理部门审核,税务机关主管负责人签字,加盖税务机关公章后,书面通知纳税人。对企业所得税检查中发现的一般性违法问题,凡不需要立案查处的,检查完毕后,由检查小组填写税务检查处理决定书,经业务管理部门审核,按规定程序报批后,通知纳税人执行。对检查中发现需要立案处理的问题,检查小组长应按规定程序填制税务检查报告,送交审理部门进行审理,审理部门按规定审理完毕后,填制税务处理决定书,经审批后,由有关部门执行。对涉嫌构成犯罪的,经批准,填制税务违法案件移送书,移交有关部门处理。
第二十七条 企业所得税检查结束后,有关业务管理部门应认真分析检查中发现的问题,对属于税务部门内部管理方面的问题,应及时整顿改进企业所得税管理工作;对属于纳税人方面的问题,应有针对性地加强宣传辅导;对属于政策方面的漏洞应及时向上级税务机关汇报。
第二十八条 各级税务机关应在每年年终对上一年度企业所得税检查工作情况进行认真总结,并以书面形式,逐级上报。省级税务机关应在每年3月底之前将全省(自治区、直辖市、计划单列市)上年企业所得税检查总结报告报送国家税务总局(所得税管理司)。企业所得税检查总结报告应包括企业所得税专项检查落实情况、企业所得税日常检查的总户数、查补的企业所得税税款、检查中发现的主要问题和典型案例以及政策建议等。
第五章 附则
第二十九条 本办法由国家税务总局负责解释,各省(自治区、直辖市和计划单列市)税务机关可以根据本地情况,制定贯彻落实本办法的补充规定。
第三十条 本办法自发布之日起执行。
Provisions for Drug Insert Sheets and Labels
Commissioner of SFDA
Provisions for Drug Insert Sheets and Labels
(SFDA Decree No.24)
The Provisions for Drug Insert Sheets and Labels, adopted at the executive meeting of the State Food and Drug Administration on March 10, 2006, is hereby promulgated and shall go into effect as of June 1, 2006.
Shao Mingli
Commissioner of SFDA
March 15, 2006
Provisions for Drug Insert Sheets and Labels
Chapter I General Provisions
Article 1 The Provisions are enacted with a view to regulating drug insert sheets and labels in accordance with the Drug Administration Law of the People’s Republic of China and the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China.
Article 2 The insert sheets and labels of drugs marketed within the territory of the People’s Republic of China shall meet the requirements of the Provisions.
Article 3 Drug insert sheets and labels shall be reviewed and approved by the State Food and Drug Administration.
A drug shall be labeled on the basis of its insert sheet. The content of the label shall be within the scope of the insert sheet. Any words and marks with implied therapeutic effects, misleading information on usage, or inappropriate promotion of the product shall not be printed.
Article 4 A drug label shall be printed on or affixed to the drug package, and no other written words, audio and/or visual materials or other information are attached to introduce or publicize the product or the enterprise.
An insert sheet shall be attached to the smallest package provided by the drug manufacturer for marketing.
Article 5 The wording in drug insert sheets and labels shall be scientific, standardized and accurate. The insert sheet of a non-prescription drug shall be written intelligibly and convenient for patients to judge, choose and use the drug on their own.
Article 6 In the label or insert sheet, the letters or characters shall be clear and easy to be recognized and the marks shall be clear and distinctive. The label and insert sheet shall have no print faded and shall not be affixed unsteadily. Any addition or modification shall not be made by means of pasting, cutting or altering.
Article 7 Drug insert sheets and labels shall be written in standardized Chinese characters published by the National Language Commission. The versions in other languages shall comply with the Chinese version.
Article 8 With the aim to protect public health and direct the rational use of drugs, drug manufacturers may voluntarily apply to add warnings to drug insert sheets or labels. The State Food and Drug Administration may also request drug manufacturers to add warnings to drug insert sheets or labels.
Chapter II Drug Insert Sheet
Article 9 A drug insert sheet shall include the significant scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use of drugs. The specific format, content and writing requirements of drug insert sheet shall be prescribed and issued by the State Food and Drug Administration.
Article 10 Disease names, pharmaceutical terms, drug names, the names and results of clinical testing in drug insert sheets shall be expressed in professional terms published or standardized by the State. The units of measurement shall conform to the national standards.
Article 11 All the active ingredients or medicinal ingredients of traditional Chinese medicines in a prescription shall be listed in the insert sheet. For injections and non-prescription drugs, all excipients shall be listed as well.
The ingredients or excipients included in a prescription, which may cause severe adverse reaction, shall be specified.
Article 12 A drug manufacturer shall trace the safety and efficacy of its marketed drugs. For any modification to the insert sheet, an application shall be submitted timely.
The State Food and Drug Administration may also require a drug manufacturer to make modification to the insert sheet on the basis of the results of adverse drug reaction monitoring and drug re-evaluation.
Article 13 After the modification to the insert sheet is approved, the drug manufacturer shall inform relevant drug distributors, drug users and other departments of the modified content immediately, and use the modified insert sheet and label timely as required.
Article 14 The insert sheet shall provide full information on adverse drug reaction and indicate the adverse reactions in detail. A drug manufacturer, who fails to timely modify the insert sheet on the basis of the safety and efficacy data of the marketed drug or to fully explain the adverse reaction in the insert sheet, shall be liable for all the consequences arising therefrom.
Article 15 The approval date and the modification date shall be distinctively shown in the insert sheet.
Chapter III Drug Labels
Article 16 Drug labels refer to the information printed or pasted on drug packaging, including inner labels and outer labels. Inner labels refer to those that appear on immediate packaging; outer labels are those on the other packaging outside of inner labels.
Article 17 The inner label shall bear such drug information as the adopted name in China, indications or functions, strength, dose and usage, production date, batch number, expiry date and manufacturer. If there is no enough space in the package to include all the information mentioned above, the adopted name in China, strength, batch number and expiry date shall be indicated at least.
Article 18 The outer label of a drug shall indicate such information as the adopted name in China, ingredients, description, indications or functions, strength, dose and usage, adverse reactions, contraindications, precautions, storage, production date, batch number, expiry date, approval number and manufacturer. Where indications or functions, dose and usage, adverse reactions, contraindications and precautions cannot be fully noted, main information plus a “See drug insert sheet for details.” notice shall be indicated.
Article 19 The label on the package for transportation and storage shall bear at least the adopted name in China, strength, storage, production date, batch number, expiry date, approval number and manufacturer. Other information such as packaging quantity, precautions for transportation or other marks may be included when necessary.
Article 20 The label for drug substance shall include the adopted name in China, storage, production date, batch number, expiry date, applied specifications, approval number and manufacturer. Other necessary information such as packaging quantity and precautions for transportation shall also be indicated.
Article 21 Where one drug produced by a manufacturer has the same drug strength and packaging specification, the content, format and color of its labels must be the same. Where one drug produced by a manufacturer has different drug strengths or packaging specifications, its labels shall be clearly distinguished from one another, or its specifications shall be notably marked in the corresponding specification items.
Where a drug produced by a manufacturer is administrated as prescription drug and non-prescription drug respectively, their packaging colors shall be distinctly different.
Article 22 For drugs with special requirements on storage, its requirements shall be marked in the notable place of the label.
Article 23 The expiry date in the drug label shall appear in the order of year, month and day, with year shown in four digits, month and day in two digits. Its specific format shall be “Valid till XXXX year XX month” or “Valid till XXXX year XX month XX day”. It may be presented with numbers and other symbols as “Valid till XXXX.XX.” or “Valid till XXXX/XX/XX”.
For the preventive biological product, the expiry date shall be labeled according to the registration specifications approved by the State Food and Drug Administration. The expiry date of the biological product for therapeutic use shall be counted from the filling date. For other drugs, the expiry date shall be counted from the production date.
Where the expiry date is labeled to the day, it shall be marked as one day earlier than the actual expiry date; where the expiry date is labeled to the month, it shall be marked as one month earlier than the actual expiry month.
Chapter IV Use of Drug Name and Registered Trademark
Article 24 The drug name in insert sheets and labels shall conform to the nomenclature principles on the adopted name in China and trade name of drug announced by the State Food and Drug Administration, and shall be consistent with those appeared in the approval documents of the drug.
Article 25 The adopted name in China shall be conspicuous and prominent, and its typeface, size and color shall be consistent, and meet the following requirements:
(1) For horizontal labels, the adopted name in China shall appear in a prominent position within the area of the upper one-third of the label; for vertical labels, it shall appear in a prominent position within the area of the right one-third of the label;
(2) No such illegible typefaces as cursive characters and seal characters shall be used, and no such format as italics, margining and shading shall be used to modify the typefaces.
(3) The font color of the adopted name in China shall be black or white, in sharp contrast to the light-colored or dark-colored background respectively.
(4) Writing in separate lines shall be avoided unless limited by the packaging size.
Article 26 The trade name of a drug shall not be placed in the same line with the adopted name in China; its typeface and color shall be no more conspicuous than that of the adopted name in China, and its font area per character shall be no bigger than half of that of the adopted name in China.
Article 27 Unregistered trademarks and other drug names unapproved by the State Food and Drug Administration shall not be used in the drug insert sheets and labels.
Where a registered trademark is used in a drug label, it shall be printed in a corner of the label. Where a registered trademark contains characters, the font area per character shall be no bigger than a quarter of that of the adopted name in China.
Chapter V Other Provisions
Article 28 For narcotic drugs, psychotropic substances, medicinal toxic drugs, radioactive pharmaceuticals, drugs for topical use, non-prescription drugs and other drugs having special marks specified by the State, their special marks shall be printed in the drug insert sheets and labels.
Where there are special provisions issued by the State for drug insert sheets and labels, they shall prevail.
Article 29 The labeling provisions for Chinese crude drugs and prepared slices of Chinese crude drugs shall be formulated separately by the State Food and Drug Administration.
Article 30 Where drug insert sheets and labels are not in compliance with the Provisions, a punishment shall be imposed in accordance with the relevant provisions of the Drug Administration Law of the People’s Republic of China.
Chapter VI Supplementary Provisions
Article 31 These Provisions shall come into force as of June 1, 2006. the Provisions for Drug Packaging, Labels and Insert Sheets (Provisional) issued by State Food and Drug Administration on October 15, 2005 shall be annulled therefrom.